Roivant re­veals its newest 'vant,' try­ing to re­boot an Ei­sai blood can­cer pro­gram and out­flank Mer­ck, Bris­tol My­ers

Roivant Sci­ences wel­comed the newest ad­di­tion to its fam­i­ly of “vants” on Mon­day dur­ing its fourth quar­ter and full-year 2021 up­date.

The bio­phar­ma un­veiled Hema­vant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER